Last reviewed · How we verify
NCT06089668
An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
trial testing Observational Study in Melioidosis in 200 participants. Completed in 2 February 2025.
31 October 2024
Quick facts
| Lead sponsor | AN2 Therapeutics, Inc |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 November 2023 |
| Primary completion | 31 October 2024 |
| Estimated completion | 2 February 2025 |
| Sites | 3 locations across Laos, Thailand |
Drugs / interventions tested
- Observational Study — full drug profile →
Conditions studied
- Melioidosis — all drugs for Melioidosis →
Sponsor
AN2 Therapeutics, Inc — full company profile →
Who can join
18 and older, any sex, with Melioidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective observational study to evaluate clinical characteristics, current practice and outcomes of adult patients (age ≥18 years) with suspected or confirmed melioidosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06089668
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational Study
Trials testing the same drug.
- NCT07534046 — Impact of Metabolic Disorders on cACLD Outcomes · not yet recruiting
- NCT07353138 — Preoperative Neutrophil-to-Lymphocyte Ratio and Early Postoperative Pain After Septorhinoplasty · not yet recruiting
- NCT07151768 — Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension · recruiting
- NCT06601439 — Utilization of Maternal Healthcare Services and Infant Feeding Practices · active not recruiting
- NCT06702436 — Invasive vs. Conservative Management in Cancer Patients With Non-ST Elevation MI (CAN-NSTEMI)" · completed
Other recruiting trials for Melioidosis
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
Other AN2 Therapeutics, Inc trials
Trials by the same sponsor.
- NCT05995444 — A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects · Phase 1 · completed
- NCT05327803 — Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease · Phase 2, PHASE3 · terminated
- NCT05283746 — A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function · Phase 1 · completed
- NCT04892641 — Phase 1 Study of Epetraborole Tablets · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06089668 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AN2 Therapeutics, Inc
- Last refreshed: 31 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06089668.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing